Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

Annals of Neurology

Volumn 78, Issue 2, 2015, Pages 248-257

  Warren Olanow, C ^a   Bartus, Raymond T ^b   Baumann, Tiffany L ^c   Factor, Stewart ^d   Boulis, Nicholas ^d   Stacy, Mark ^e   Turner, Dennis A ^e   Marks, William ^f   Larson, Paul ^f   Starr, Phillip A ^f   Jankovic, Joseph ^g   Simpson, Richard ^g   Watts, Ray ^h   Guthrie, Barton ⁱ   Poston, Kathleen ^j   Henderson, Jaimie M ^j   Stern, Matthew ^k   Baltuch, Gordon ^k   Goetz, Christopher G ^l   Herzog, Christopher ^m   Jeffrey, H ^l   Alterman, Ron ⁿ   Lozano, Andres M ^o   Lang, Anthony E ^o   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b RTBioconsultants Inc   (United States)

^c ISIS PHARMACEUTICALS   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h The University of Alabama at Birmingham   (United States)

ⁱ University of Alabama at Birmingham   (United States)

^j STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

^m Ceregene   (United States)

ⁿ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^o UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEURTURIN; NRTN PROTEIN, HUMAN;

ADENO ASSOCIATED VIRUS 2; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BALANCE DISORDER; BRADYCARDIA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EYE SWELLING; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERSALIVATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; NAUSEA; NERVE FIBER TRANSPORT; NEURALGIA; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PARKINSON DISEASE; PARKINSONISM; PRESYNCOPE; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; SUBSTANTIA NIGRA; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; CLINICAL TRIAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; THERAPEUTIC USE; TREATMENT OUTCOME;

AGED; AXONAL TRANSPORT; DEPENDOVIRUS; DOUBLE-BLIND METHOD; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; NEURTURIN; PARKINSON DISEASE; PUTAMEN; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 84937734362     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24436     Document Type: Article

References (26)

1. Gash DM, Zhang Z, Ovadia A, et al., Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-255.
2. Kordower JH, Emborg ME, Bloch J, et al., Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-773.
3. Nutt JG, Burchiel KJ, Comella CL, et al., Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60: 69-73.
4. Lang AE, Gill S, Patel NK, et al., Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459-466.
5. Kordower JH, Palfi S, Chen EY, et al., Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46: 419-424.
6. Salvatore MF, Ai Y, Fischer B, et al., Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006; 202: 497-505.
7. Kotzbauer PT, Lampe PA, Heuckeroth RO, et al., Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996; 384: 467-470.
8. Herzog CD, Dass B, Holden JE, et al., Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007; 22: 1124-1132.
9. Kordower JH, Herzog CD, Dass B, et al., Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006; 60: 706-715.
10. Gasmi M, Herzog CD, Brandon EP, et al., Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 2007; 15: 62-68.
11. Herzog CD, Dass B, Gasmi M, et al., Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther 2008; 16: 1737-1744.
12. Marks WJ Jr, Ostrem JL, Verhagen L, et al., Gene transfer of a trophic factor for Parkinson's disease: initial clinical trial with AAV2-neurturin (CERE-120). Lancet Neurol 2008; 7: 400-408.
13. Marks W, Bartus R, Siffert J, et al., Double-blind, sham-surgery controlled trial of gene delivery of AAV2-neurturin for Parkinson's disease. Lancet Neurol 2010; 9: 1164-1172.
14. Bartus RT, Herzog CD, Chu Y, et al., Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2011; 26: 27-36.
15. Bartus RT, Kordower JH, Johnson EM, et al., Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synuclienopathies. Neurobiol Dis 2015; 78: 162-171.
16. Manfredsson FP, Tumer N, Erdos B, et al., Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 2009; 17: 980-991.
17. Su X, Kells AP, Huang EJ, et al., Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009; 20: 1627-1640.
18. Herzog CD, Brown L, Kruegel BR, et al., Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiol Dis 2013; 58: 38-48.
19. Bartus RT, Brown L, Wilson A, et al., Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 2011; 44: 38-52.
20. Bartus RT, Baumann TL, Siffert J, et al., Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson's disease. Neurology 2013; 80: 1698-1701.
21. Bartus RT, Weinbert MS, Samulski RJ,. Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther 2014; 22: 487-497.
22. Decressac M, Kadkhodaei B, Mattsson B, et al., α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 2012; 4: 163ra156.
23. Chung CY, Koprich JB, Siddiqi H, Isacson O,. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 2009; 29: 3365-3373.
24. Kordower JH, Olanow CW, Dodiya HB, et al., Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013; 136: 2419-2431.
25. Bartus RT,. CERE-120 (AAV2-NRTN) for the treatment of Parkinson's disease: experience from 4 clinical trials and human autopsy data. Paper presented at: Sixteen Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT); May 17, 2013; Salt Lake City, UT.
26. Alterman RL, Tagliati M, Olanow CW,. Open-label surgical trials for Parkinson's disease: time for reconsideration? Ann Neurol 2011; 70: 5-8.